-
公开(公告)号：US20110276131A1
公开(公告)日：2011-11-10
申请号：US13184690
申请日：2011-07-18
申请人： Eugene de Juan, JR. , Stephen Boyd , Cary Reich , Alan Rapacki , Hanson S. Gifford, III , Mark Deem
发明人： Eugene de Juan, JR. , Stephen Boyd , Cary Reich , Alan Rapacki , Hanson S. Gifford, III , Mark Deem
IPC分类号： A61F2/14
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.
摘要翻译： 用于插入通过泪点并进入患者的小管腔的植入物。 植入物包括材料基质，分散在材料基质中的治疗剂，鞘层，其设置在材料基质的一部分上并且被配置为抑制治疗剂从材料基质释放到小管腔内，并且 允许治疗剂从材料基质的表面释放到泪膜，以及构造成将植入物保持在小管腔内的保留结构。
-
公开(公告)号：US07998497B2
公开(公告)日：2011-08-16
申请号：US11695545
申请日：2007-04-02
申请人： Eugene de Juan, Jr. , Stephen Boyd , Cary Reich , Alan Rapacki , Hanson S. Gifford, III , Mark Deem
发明人： Eugene de Juan, Jr. , Stephen Boyd , Cary Reich , Alan Rapacki , Hanson S. Gifford, III , Mark Deem
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： Implant devices, systems and methods for insertion into a punctum of a patient optionally comprises a drug core and a sheath body disposed over the drug core. The drug core includes a therapeutic agent deliverable into the eye, and the sheath defines at least one exposed surface of the drug core. The exposed surface(s) of the drug core may contact a tear or tear film fluid and release the therapeutic agent at therapeutic levels over a sustained period when the implant is implanted for use. The implant may include a retention element to retain the drug core and sheath body near the punctum, optionally comprising a shape memory alloy that can resiliently expand. An occlusive element may be attached to the retention element to at least partially occlude tear flow through the canalicular lumen.
摘要翻译： 用于插入患者泪点的植入装置，系统和方法可任选地包括药物核心和设置在药物核心上方的鞘体。 药物核心包括可递送到眼睛中的治疗剂，护套限定药物核心的至少一个暴露表面。 药物核心的暴露表面可以接触泪液或泪膜流体，并且当植入物植入使用时在持续的时间内以治疗水平释放治疗剂。 植入物可以包括保持元件，以将药物核心和鞘体保持在泪点附近，任选地包括可弹性膨胀的形状记忆合金。 闭塞元件可以连接到保持元件以至少部分地封闭穿过小管腔的泪液流动。
-
公开(公告)号：US08747884B2
公开(公告)日：2014-06-10
申请号：US13184690
申请日：2011-07-18
申请人： Eugene De Juan, Jr. , Stephen Boyd , Cary Reich , Alan Rapacki , Hanson S. Gifford , Mark Deem
发明人： Eugene De Juan, Jr. , Stephen Boyd , Cary Reich , Alan Rapacki , Hanson S. Gifford , Mark Deem
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.
摘要翻译： 用于插入通过泪点并进入患者的小管腔的植入物。 植入物包括材料基质，分散在材料基质中的治疗剂，鞘层，其设置在材料基质的一部分上并且被配置为抑制治疗剂从材料基质释放到小管腔内，并且 允许治疗剂从材料基质的表面释放到泪膜，以及构造成将植入物保持在小管腔内的保留结构。
-
4.发明申请Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System 审中-公开药物输送方法，结构和组合物用于鼻泪管系统公开(公告)号：US20090092654A1
公开(公告)日：2009-04-09
申请号：US12332219
申请日：2008-12-10
IPC分类号： A61L27/54 , A61L27/58 , A61K38/13 , A61K31/5377 , A61K31/215 , A61K31/165 , A61P27/02 , A61P27/06
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.
摘要翻译： 用于插入患者的泪点的植入物包括主体。 主体具有远端，近端和它们之间的轴线。 身体的远端可以通过泪点向远端插入到小管腔内。 身体包含药剂基质药物核心内的治疗剂。 试剂基质暴露于泪液能够在持续的时间内有效的治疗剂释放到泪液中。 身体具有设置在药剂基质上的护套以抑制药剂远离近端的释放。 身体还具有被配置为接合腔壁组织的外表面，以便当设置在其中时阻止排出。 在具体实施方案中，试剂基质包含非生物可吸收聚合物，例如与该试剂的非均匀混合物的硅氧烷。
-
5.发明授权公开(公告)号：US08795711B2
公开(公告)日：2014-08-05
申请号：US11695537
申请日：2007-04-02
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.
摘要翻译： 用于插入患者的泪点的植入物包括主体。 主体具有远端，近端和它们之间的轴线。 身体的远端可通过泪点向远端插入到小管腔内。 身体包含药剂基质药物核心内的治疗剂。 试剂基质暴露于泪液能够在持续的时间内有效的治疗剂释放到泪液中。 身体具有设置在药剂基质上的护套以抑制药剂远离近端的释放。 身体还具有被配置为接合腔壁组织的外表面，以便当设置在其中时阻止排出。 在具体实施方案中，试剂基质包含非生物可吸收聚合物，例如与该试剂的非均匀混合物的硅氧烷。
-
公开(公告)号：US20070243230A1
公开(公告)日：2007-10-18
申请号：US11695545
申请日：2007-04-02
申请人： Eugene de Juan , Stephen Boyd , Cary Reich , Alan Rapacki , Hanson Gifford , Mark Deem
发明人： Eugene de Juan , Stephen Boyd , Cary Reich , Alan Rapacki , Hanson Gifford , Mark Deem
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： Implant devices, systems and methods for insertion into a punctum of a patient optionally comprises a drug core and a sheath body disposed over the drug core. The drug core includes a therapeutic agent deliverable into the eye, and the sheath defines at least one exposed surface of the drug core. The exposed surface(s) of the drug core may contact a tear or tear film fluid and release the therapeutic agent at therapeutic levels over a sustained period when the implant is implanted for use. The implant may include a retention element to retain the drug core and sheath body near the punctum, optionally comprising a shape memory alloy that can resiliently expand. An occlusive element may be attached to the retention element to at least partially occlude tear flow through the canalicular lumen.
摘要翻译： 用于插入患者泪点的植入装置，系统和方法可任选地包括药物核心和设置在药物核心上方的鞘体。 药物核心包括可递送到眼睛中的治疗剂，护套限定药物核心的至少一个暴露表面。 药物核心的暴露表面可以接触泪液或泪膜流体，并且当植入物植入使用时在持续的时间内以治疗水平释放治疗剂。 植入物可以包括保持元件，以将药物核心和鞘体保持在泪点附近，任选地包括可弹性膨胀的形状记忆合金。 闭塞元件可以连接到保持元件以至少部分地封闭穿过小管腔的泪液流动。
-
公开(公告)号：US08814819B2
公开(公告)日：2014-08-26
申请号：US12970482
申请日：2010-12-16
CPC分类号： A61F9/00781 , A61B34/70 , A61B90/00 , A61F2/14 , A61F2/142 , A61F9/0008 , A61F9/0017 , A61F9/007 , A61F9/00736 , A61F9/0133 , A61F11/00 , A61F2250/0001 , A61F2250/0096 , A61F2250/0097 , A61K9/0051 , A61M27/002 , A61M2202/04 , A61M2210/0612
摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.
-
公开(公告)号：US08801649B2
公开(公告)日：2014-08-12
申请号：US12898593
申请日：2010-10-05
CPC分类号： A61F9/00781 , A61B34/70 , A61B90/00 , A61F2/14 , A61F2/142 , A61F9/0008 , A61F9/0017 , A61F9/007 , A61F9/00736 , A61F9/0133 , A61F11/00 , A61F2250/0001 , A61F2250/0096 , A61F2250/0097 , A61K9/0051 , A61M27/002 , A61M2202/04 , A61M2210/0612
摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.
摘要翻译： 方法和装置适于植入眼睛。 在眼睛的角膜中形成切口，并且通过切口将分路插入眼睛的前房。 分流器包括流体通道。 所述分流器沿着从所述前房通过所述眼睛的巩膜刺入所述脉管外空间的路径通过并且定位在第一位置，使得所述流体通道的第一部分与所述前房连通，并且所述流体通道的第二部分 与脉管外空间连通，以在脉络膜上空间和前房之间提供流体通道。
-
公开(公告)号：US08734378B2
公开(公告)日：2014-05-27
申请号：US12561680
申请日：2009-09-17
CPC分类号： A61F9/00781 , A61B34/70 , A61B90/00 , A61F2/14 , A61F2/142 , A61F9/0008 , A61F9/0017 , A61F9/007 , A61F9/00736 , A61F9/0133 , A61F11/00 , A61F2250/0001 , A61F2250/0096 , A61F2250/0097 , A61K9/0051 , A61M27/002 , A61M2202/04 , A61M2210/0612
摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.
-
公开(公告)号：US20110028883A1
公开(公告)日：2011-02-03
申请号：US12898593
申请日：2010-10-05
CPC分类号： A61F9/00781 , A61B34/70 , A61B90/00 , A61F2/14 , A61F2/142 , A61F9/0008 , A61F9/0017 , A61F9/007 , A61F9/00736 , A61F9/0133 , A61F11/00 , A61F2250/0001 , A61F2250/0096 , A61F2250/0097 , A61K9/0051 , A61M27/002 , A61M2202/04 , A61M2210/0612
摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.
-
-
-
-
-
-
-
-
-
搜索结果
85 条记录 (耗时 0.046 秒)
